Clinical Trial: SGLT2i Effect on PTDM Development and Kidney Allograft Function in Non-diabetic Kidney Transplant Recipients: A Randomized, Doubleblind, Placebo Controlled, National Multicenter Trial

U.S., July 3 -- ClinicalTrials.gov registry received information related to the study (NCT07682350) titled 'SGLT2i Effect on PTDM Development and Kidney Allograft Function in Non-diabetic Kidney Transplant Recipients: A Randomized, Doubleblind, Placebo Controlled, National Multicenter Trial' on June 19.

Brief Summary: The goal of this clinical trial is to find out whether 12 months of treatment with the SGLT2 inhibitor Forxiga(R) (dapagliflozin 10 mg once daily), compared with placebo, can reduce the risk of developing post-transplant diabetes in kidney transplant recipients who do not have diabetes at the time of transplantation.

The main questions it aims to answer are:

* Does Forxiga reduce the risk of developing post-transplant diabe...